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ABSTRACT:
Background: The efficacy of combination therapy in previous non responders to
interferon (IFN) monotherapy with chronic hepatitis C is lower than in naïve patients,
and there has been no economic evaluation in this population.
Aim: To develop a cost-effectiveness analysis of therapeutic regimens with IFN
alpha and ribavirin in previous interferon non-responders.
Methods: A Markov simulation model was used to project the clinical and
economic outcomes of five different therapeutic strategies including a “no treatment”
alternative using the health care system perspective. The effectiveness data for the
different doses and durations was obtained from a previously performed meta-analysis.
A sensitivity analysis was performed to test robustness of the model, analysing changes
in different variables.
Results: Applying a 3% discount rate, the standard patient on combination
therapy for 12 months showed an increase of 0.80 years and 1.55 quality adjusted life
years (QALYs), when comparing combination therapy for 12 months vs. “no treatment”
strategy. This option led to an incremental cost-effectiveness ratio of 11,767 euros per
year of life gained and 6,073 euros per QALY.
Conclusions: Combination therapy with interferon plus ribavirin in previous
interferon non-responders shows an incremental cost-effectiveness ratio within the
range of some well accepted medical interventions in our health care system.
Key words: Hepatitis C; Interferon; Markov model; Non-responders; ribavirin.
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INTRODUCTION
Chronic hepatitis C is the leading cause of chronic liver disease and liver
transplantation in Western Europe and the United States. Over 4 million individuals are
infected with hepatitis C virus (HCV) in the USA, and more than 5 million are
estimated in Western Europe, of whom 800,000 are in Spain1-3.
Chronic hepatitis C represents an important public health problem. Firstly,
because of the large number of patients infected, and secondly because it is a
progressive disease that may lead to cirrhosis, liver failure and hepatocellular
carcinoma, resulting in a loss of life expectancy and a decline in the quality of life. The
complications of chronic hepatitis C are associated with high health care costs,
particularly for advanced liver disease, which often requires liver transplantation.
Monotherapy with alpha interferon (IFN) was the first effective treatment for
chronic hepatitis C4. Later, ribavirin was combined with interferon for 6 or 12 months
depending on HCV genotype. The combination of interferon plus ribavirin increased
end of treatment response and sustained response by reducing the relapse rate. The
sustained virologic response, i.e. viral clearance 6 months after the end of therapy, is
higher in naïve patients than in previous interferon non-responders. Currently,
combination therapy is the standard of care for patients with chronic hepatitis C. Its role
in interferon non-responders is still controversial but some meta-analyses suggest an
acceptable rate of sustained virologic response in this population5.
Several cost-effectiveness studies on interferon monotherapy and combination
therapy in naïve and relapser patients have been published 6-14, but none on combination
therapy for previous interferon non-responders. Since the efficacy of combination
therapy in this population is lower than in naïve patients, cost-effectiveness analysis
could be useful in building guidelines for collective decision making in health care
systems.
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The aim of this study is to estimate the cost-effectiveness of different therapeutic
regimens with IFN alpha and ribavirin for patients with chronic hepatitis C previously
non-responders to interferon monotherapy.
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MATERIALS AND METHODS
Patient characteristics and virological treatment response rates were taken from a
hypothetical cohort of previous non-responder patients reported in a recent meta-
analysis carried out by our group5. The details of this study have been published
previously. The standard patient was a 42 year-old man from a cohort of patients with
histological lesions of chronic hepatitis C in 88% of cases (21% mild and 66%
moderate), and compensated cirrhosis in 13%. The distribution of histological lesions
was obtained from the studies included in the meta-analysis5.
Decision-Analytic Model
A Markov decision analysis model, based on previous validated examples
from the literature5,7,10, was used to describe disease progression and determine the
long-term morbidity, life expectancy and lifetime costs of different treatment
strategies based on the time spent in each clinical state for the hypothetical cohort.
This model simulates the course of the disease from its initial stages of mild disease
until death due to liver-related or other causes, and the effects of IFN monotherapy
and combination therapy on the outcome of the disease (Figure 1). The model uses
probabilities of progression from chronic hepatitis to cirrhosis, decompensated liver
disease and finally death, obtained from the results of several published studies
validated in previous analyses6,8,11 (Table 1).
During the follow-up, represented by annual cycles, the patient may remain in
the same clinical state, progress to another state, die from liver disease, die from other
causes, or go up to a healthy state if a sustained virological response is achieved. The
resources used and the costs for the different strategies have been estimated based on
data published in previous studies9,11.
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Calculations were done with DATA 3.5 (Tree-Age Software, Inc Boston
Massachusetts). Outcome calculations were performed in years of life gained, and also
in quality adjusted life years (QALYs), including utility assignments associated with
each health state.
Therapeutic options
Five different strategies were examined. Strategy 1: No treatment; Strategy 2:
IFN monotherapy for  6 months; Strategy 3: Combination therapy for 6 months with
standard doses of IFN; Strategy 4: Combination therapy for 6 months with high doses of
IFN; Strategy 5: Combination therapy for 12 months with standard doses of IFN.
All patients were treated for the total period of time. The characteristics of these
therapeutic alternatives, their effectiveness and costs are shown in Table 2.
Health-Related Quality of Life
The quality of life analysis was performed with assigned estimates of utility for
each health state determined by a panel of hepatologists. These utility assignments are
based on those published by Bennett6 and Wong8 and ranged from “1” (viral
negativity) to “0” (death). To calculate quality-adjusted life years (QALYs), the time
spent in each health state according to the projected model was multiplied by each
utility value. Those figures were adjusted to the healthy population quality of life
value for Spain15, 0.89 on a 0-1 scale, obtained from the visual analogue scale of the
EQ-5D questionnaire (Table 3).
Cost data, discount rate and perspective
In the analysis, all direct health care costs, i.e., of screening patients for therapy,
diagnostic and laboratory tests, drugs, monitoring during therapy and follow-up, and
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hospital stays (for each specific health care state that might require hospitalisation)
were included. The annual costs of disease states considered in the model were based
on previous reports obtained from the Spanish health care system’s cost database
SOIKOS9,11. All costs were converted to year 2001 euros using the Consumer Price
Index (Table 4). No indirect costs, such as lost workdays, loss of productivity, nor
intangible costs related to patient suffering were included in this model.
The perspective adopted in the analysis was that of the Spanish national health
care system, which is the final payer of direct treatment costs over the patients’
lifetimes.
Discounting was used to consider time preference, converting both future costs
and health benefits into present values. A discount rate of 3% was applied to costs and
health benefits, based on international recommendations16.
Drug costs were obtained from current pharmaceutical prices charged to the
Spanish health care system, that is 6.01 euros for 1 MU of IFN alpha and  22.60 euros
for 1 g of Ribavirin.
Health care costs for treatment monitoring were based on general clinical
practice9,11 and included: first specialist visit (144.3 euros), follow-up visits (72.4
euros), laboratory testing (22.14 euros), HCV-RNA determination (68.3 euros), and
TSH determination (9.77 euros).
Total cost calculation for each option, as shown in Table 4, included total drug
costs, health care resources costs based on previously cited unit prices, the cost of
ribavirin induced haemolytic anaemia, and the cost of monitoring patients who
responded to treatment (even those who relapsed), consisting of one follow-up visit, one
laboratory test and one hepatitis C virus RNA determination. The cost of haemolytic
anaemia was estimated at around 1% of 12 months’ combination therapy cost17. This
side effect represents the main differential adverse effect between combination therapy
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and monotherapy with IFN and not considering it would have biased the results against
the IFN monotherapy option.
No therapy costs were considered in strategy 1 since the health resources in
strategies 2 to 5 were drug monitoring costs (drugs, lab tests, visits …), not including
routine visits or other possible health resources.
Assumptions
The natural history model assumes a constant rate of disease progression over
time as in other published cost-effectiveness studies6,8-13. The model assumes that a
sustained response (normal serum alanine aminotransferase levels and hepatitis C virus
RNA negativity) at 6 months of follow-up is equivalent to a prolonged response and,
therefore a “cure”. Furthermore, a cure is considered to restore population-specific life
expectancy. Similarly, non-responders or relapsers are considered to gain no benefit
from therapy.
An inherent restriction of Markov models is their reliance on the “Markovian
assumption”. This states that the behaviour of the process subsequent to any cycle
depends only on its description in that cycle. That is, the process has no memory for
earlier cycles.
The model assumes that disease progression and treatment efficacy are equal for
all age groups, due to the lack of evidence on age dependent differences.
The incremental cost-effectiveness ratio was calculated as the additional cost
divided by the number of years of increased life expectancy or the increase in QALYs
for the options compared. Most well accepted medical interventions in our health care
system environment have incremental cost-effectiveness ratios falling below 30,000
euros per QALY18-20.
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Sensitivity analysis
A one-way sensitivity analysis for some of the uncertain variables used in the
model was performed, in order to identify how changes would affect costs and
therapeutic outcomes. The following variables were modified: the discount rate from
0% to 5%, the patients ages at the start of therapy from 30 to 60 years, some
probabilities of progression between the different states of chronic hepatitis C disease
including liver transplantation were doubled and halved and effectiveness data along the
confidence interval for each strategy, keeping the base case figures for the other
strategies.
A therapeutic option using 5 MU of IFN daily in combination therapy studied by
Puoti et al, was also evaluated21. This option was included in the sensitivity analysis
because, despite the small number of patients treated (21 patients), it showed a sustained
virological response of 40%, making it an interesting option to study in depth, both
from a clinical and pharmacoeconomic point of view.
Model validation
The validity of the model was tested by predicting the life expectancy for a
healthy 42-year-old man, 34.72 years, which is very similar to the Spanish average life
expectancy of 34.09 years. For a cohort of patients with compensated cirrhosis, we
predicted a 5-year survival rate of 48%, similar to the 50% described by Fattovich et al
and to the 55% predicted by Bennett's model6,22.
The life expectancy for a 42-year-old patient with different states of chronic
hepatitis C disease was also calculated: 26.48 years with chronic hepatitis, 18.17 years
with cirrhosis and  6.12 years with decompensated cirrhosis. These  results reflect the
natural history of hepatitis C.
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Support source
This pharmacoeconomic study was performed exclusively as an academic work,
and has not been supported by any pharmaceutical company, government agency or
grant.
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RESULTS
Base-Case Analysis.
Five strategies were applied to a base-case patient cohort of previous non-
responders to IFN. The highest sustained virological response, 20.5%, was achieved
with strategy 5, that is treating non responders with combination therapy for 12 months.
The pharmacoeconomic results for each strategy are shown in tables 5 and 6. The
highest increase in life expectancy, applying a 3% discount rate, was observed with
strategy 5, with an increase of 0.8 years of life and 1.55 QALYs. The incremental cost-
effectiveness ratio (ICER) between the four therapeutic strategies (strategies 2-5) vs.
“no treatment” (strategy 1) was calculated as well as for each strategy and the next most
effective one (Figure 2).
Figure 2 shows the “efficiency frontier” that is given by the lines joining
strategies 1 (the origin), 4 and 5. There is no simple dominance in this analysis, which
means that an alternative has higher costs and lower effectiveness than some other
option. Nevertheless, strategies 2 and 3 can be ruled out through the principle of
extended dominance16. Under this concept, a strategy is not surpassed by any other
alternative (as in simple dominance) but by a mixed strategy of two other programs. In
this case, a combination of strategies 1 and 4 can produce more QALYs and be less
costly than strategies 2 and 3.
All the figures obtained from the analysis fall below the benchmark cost per
QALY of many well-accepted medical interventions in Spain and other countries18-20.
Sensitivity Analysis.
Table 7 shows results of sensitivity analysis. The age at the start of treatment is
a variable that significantly affects the results. Increasing this variable reduces the
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benefits while raising costs. Ages less than 60 years show a cost-effectiveness ratio
lower than the benchmark of well-accepted medical interventions.
Discount rates were modified showing a decrease in the ICER for 12 months of
combination therapy vs. “no treatment” of 2,450 euros per year of life gained without
discounting, while it rose to 9,329 euros with an annual discount rate of 5%.
Annual progression rates from mild to moderate chronic hepatitis C and from
moderate chronic hepatitis C to cirrhosis were also modified from half to twice their
original value. A very small change in the ICER was observed when the annual
progression rate between mild to moderate disease was modified but a more significant
impact was observed when the progression rate from moderate disease to cirrhosis was
changed.
Effectiveness data were analysed throughout the confidence interval values.
Using the lower end of the confidence interval for strategy 5 (IC95%: 15.5%-26.0%),
cost-effectiveness ratio of strategy 5 vs. 4 reached the figure of 62,900 € per QALY.
Cost-effectiveness ratio of strategy 4 vs. 3 was evaluated throughout the 95%
confidence interval (95%CI: 10.2%-19.9%) of strategy 4. Using the upper limit for
strategy 4 led strategy 3 to become a dominated option (strategy 4 was more effective
and less costly due to future costs saved as a consequence of the increase in
effectiveness). The lower bound of the confidence interval did not need a cost-
effectiveness ratio calculation since strategy 4 is less effective and more costly.
Applying the same procedure to the upper end of strategy 5, and extreme values
of 95% confidence interval of strategies 2 and 3, general conclusions kept unchanged.
The high daily dose schedule of interferon in combination therapy studied by
Puoti et al (5 MU of IFN daily plus ribavirin for 6 months) was also considered in the
sensitivity analysis. The cost of this option during the treatment period was 9,595 euros,
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exceeded only by 12 months combination therapy. However, the total cost (including
future costs derived from disease progression) was 17,390 euros, lower than the cost of
the three strategies using combination therapy (strategies 3-5, Table 5 and 6). With a
sustained virologic response of 40%, the high daily doses of interferon plus ribavirin
increased life years gained by 1.56 and QALYs by 3.03 years vs. “no treatment”, with
an incremental cost of 4,373 euros. The ICER for this strategy vs. the “no treatment”
option was 2,803 euros per year of life gained and 1,443 euros per QALY, giving it the
most favourable incremental cost-effectiveness ratio. However, the small number of
patients treated with this schedule does not allow robust conclusions to be made.
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DISCUSSION
This is the first study evaluating the cost-effectiveness of combination therapy in
previous IFN non responders using a decision analysis model. The study shows how the
best option with combination therapy eradicated HCV infection in 2 out of 10 treated
patients which prevented further disease complications making this therapy the most
efficient from the health care system perspective. An incremental cost per QALY
between 6,000 and 10,000 euros and from 9,000 to 20,000 euros per year of life gained
depending on the strategy is well within the range of many well-accepted medical
interventions and far below the benchmark of 30,000 euros per QALY. The
recommended alternative within the undominated options (strategies 1, 4 and 5) would
be alternative 5 (combination therapy for 12 months) because it is more effective than
strategies 1 and 4, and its incremental cost-effectiveness ratio is still under the indicated
benchmark.
However, one of the drawbacks of applying decision models to long-term
chronic diseases, like hepatitis C, is that the progression rates between disease states
may not accurately reflect real rates. The use of high progression rates may bias the
results in favour of better cost-effectiveness ratios23. However, the characteristics of
non-responder patients who usually have bad prognostic factor such as higher age, more
advanced liver disease and high levels of viremia, making the scenario more realistic
may balance this bias.
Many cost-effectiveness studies on hepatitis C have focused on untreated
patients and relapser patients. In these studies, treatment efficacy rates were obtained
from multicenter studies of interferon plus ribavirin including large numbers of patients
with chronic hepatitis C24-26. IFN non responder patients, in spite of the high proportion
they represent, have been involved in fewer clinical trials with fewer patients than other
population groups, and only two of the trials included more that 100 patients for each of
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the therapeutic options compared5,27,28. Unlike other pharmacoeconomic studies, in
which treatment efficacy rates were obtained from a pool of clinical trials without
specifying the method of estimating global efficacy, our data on sustained virological
response was obtained from a previously performed meta-analysis that considered
therapeutic strategies in depth using different dosages and durations5.
Sensitivity analysis for effectiveness data showed some important changes as
compared with the base case scenario. However extreme values of the 95% confidence
intervals seem highly improbable. But, if it were the case, since the 62,900 € / QALY of
incremental cost-effectiveness ratio of strategy 5 vs. 4 can be outside the boundaries of
accepted medical interventions, then strategy 4 could be the strategy adopted.
Some studies in untreated patients have suggested a 0.2% probability of
spontaneous resolution of hepatitis C while others do not mention about it at all. In our
model for non-responder patients spontaneous resolution was not considered because of
its rarity in this population.
On efficiency grounds, the decision to treat naïve patients with chronic hepatitis
C is sometimes difficult, particularly in patients with mild disease, low degree of
fibrosis, normal ALT levels or older age. In previous non-responders, the decision to
treat is still more difficult because the treatment response with interferon and ribavirin is
lower than in naïve patients and the probabilities of achieving a sustained virological
response are also lower. On the other hand, these patients have more aggressive disease
with a higher frequency of cirrhosis than untreated patients. Appropriate candidate
selection, good patient care and motivation, and correct management of side effects
could increase therapy compliance and therefore improve sustained virological response
rates as well as cost-effectiveness ratios. Age at the start of treatment is an important
Pharmacoeconomic analysis in Non-Responders16
factor in candidate selection, because the benefits of treating patients over 65 are small,
and the decision to treat should be individualized for each patient.
Most published studies in non-responders have focused on different therapeutic
strategies. However, data on patients baseline characteristics such as HCV genotype,
viral load, ALT levels, degree of fibrosis, etc … are too scarce to apply to cost-
effectiveness analyses. Analysing these factors, as well as new therapeutic strategies,
could improve cost-effectiveness ratios in non-responders but more studies in this
setting are necessary to obtain robust results.
In the coming years, the non-responder population will grow to become one of
the main challenges in Hepatitis C virus therapy due to their higher probabilities of
developing complications. This population, together with genotype 1 patients, will be an
important focus of future studies. Until new effective therapies appear, combination
therapy with interferon plus ribavirin for 12 months should be considered the most
efficient option for these patients.
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TABLE 1. Annual transition probabilities of progression between health states6,11.
INITIAL STATE TO % PROGRESSION
Mild chronic hepatitis C Moderate chronic hepatitis C 4.1
Moderate chronic hepatitis C Cirrhosis 7.3
Cirrhosis Hepatocellular carcinoma 1.5
Hepatic encephalopathy 0.4
Variceal bleeding 1.1
Ascites 2.5
Hepatocellular carcinoma Death 86.0
Hepatic encephalopathy Death 1st year 68.0
Death subsequent yrs. 40.0
Liver transplantation 3.1
Variceal bleeding Death 1st year 40.0
Death subsequent yrs. 13.0
Liver transplantation 3.1
Ascites Death 11.0
Refractory ascites 6.7
Liver transplantation 3.1
Refractory ascites Death 33.0
Liver transplantation Death 1st year 21.0
Death subsequent yrs. 5.7
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TABLE 2. Effectiveness, health resources use and total cost for the therapeutic
strategies considered5,9,11.
LEGENDS:
€: euros; t.t.w.: three times a week.
THERAPEUTIC STRATEGIES
1 2 3 4 5
Duration (months) - 6 6 6 12
IFN dose - 3 MU t.t.w. 3 MU t.t.w. 5 MU t.t.w. 3 MU t.t.w.
Rivabirin dose - - 1 g / day 1 g / day 1 g / day
End of treatment response 0.0% 7.5% 26.0% 29.0% 27.0%
Sustained response 0.0% 2.0% 12.5% 14.5% 20.5%
First visit - 1 1 1 1
Follow-up visits - 2 3 3 5
Lab test - 3 4 4 6
HCV-RNA test - 1 2 2 3
TSH lab test - 2 2 2 3
Drug cost (€) - 1,407 5,531 6,469 11,063
Monitoring Cost (€) - 455 603 608 917
Total cost (€) - 1,862 6,244 7,187 12,090
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TABLE 3. Utility values for health states6,11.
HEALTH STATES
ASSOCIATED 
UTILITY
Viral negative 0.89
Mild chronic hepatitis C 0.73
Moderate chronic hepatitis C 0.69
Cirrhosis 0.62
Liver transplantation (subsequent yrs.) 0.62
Liver transplantation (1st year) 0.45
Ascites 0.31
Hepatic encephalopathy 0.27
Variceal bleeding 0.25
Hepatocellular carcinoma 0.09
Death 0.00
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TABLE 4. Annual cost of clinical states involved in chronic hepatitis C progression11.
CLINICAL STATE
Euros 2001
Mild chronic hepatitis C 189
Moderate chronic hepatitis C 189
Cirrhosis 339
Ascites 1,106
Refractory ascites 8,428
Variceal bleeding (1st year) 3,857
Variceal bleeding (subsequent yrs.) 1,174
Hep. encephalopathy (1st year) 4,686
Hep. encephalopathy (subsequent yrs.) 1,196
Hepatocellular carcinoma 5,294
Liver transplantation (1st year) 108,349
Liver transplantation (subsequent yrs.) 11,965
Death 5,529
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TABLE 5. "Base case" results and incremental cost-effectiveness ratios using QALYs
as measure of outcomes.
LEGENDS:
€: euros; Ext Dom: extended dominance.
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TABLE 6. "Base case" results and incremental cost-effectiveness ratios using years of
life gained as measure of outcomes.
LEGENDS:
€: euros; Ext Dom: extended dominance.
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TABLE 7. Sensitivity analysis for Incremental cost-effectiveness ratio of different
options vs. "no treatment" in the base case patient.
LEGENDS:
€: euros.
Variable
Rank           
(lower-higher)
STRATEGY 2 
vs. 1                   
(€ / QALY)
STRATEGY 3 
vs. 1                   
(€ / QALY)
STRATEGY 4 
vs. 1                   
(€ / QALY)
STRATEGY 5  
vs. 1                   
(€ / QALY)
Age (years) 30 - 60 8,176 - 18,946 3,596 - 9,932 3,561 - 9,758 4,532 - 12,049
Discount rate (%) 0% - 5% 4,793 - 16,745 1,820 - 7,685 1,793 - 7,569 2,450 - 9,329
Annual transition probabitily 
from mild to moderate CHC
2.05% - 8.2% 10,713 - 9,959 5,000 - 4,707 4,943 - 4,637 6,193 - 5,872
Annual transition probabitily 
from moderate CHC to 
cirrhosis
3.65% - 14.6% 12,676 - 9,165 5,910 - 4,060 5,869 - 4,019 7,276 - 5,129
Annual rate of liver 
transplantation
1.55% - 6.2% 10,305 - 10,140 5,116 - 4,376 5,082 - 4,326 6,309 - 5,582
Pharmacoeconomic analysis in Non-Responders27
FIGURE 1. Hepatitis C progression health states and transitions.
LEGENDS:
CHC: chronic hepatitis C; O.L.T.: ortho liver transplant; SVR: sustained virological
response.
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Pharmacoeconomic analysis in Non-Responders28
FIGURE 2. Incremental cost-effectiveness ratio for each therapeutic strategy vs. “no
treatment” and threshold of 30,000 €/QALY.
LEGENDS:
2: 1,601 € / 0.15 QALYs; 3: 1,612 € / 0.94 QALYs; 4: 5,294 € / 1.1 QALYs; 5: 9,414 €
/ 1.55 QALYs.
€: euros; Threshold: 30,000 € / QALY.
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